Petropolis

Researchers are evaluating the effectiveness and safety of sonrotoclax combined with zanubrutinib compared to zanubrutinib with a placebo in adults who have relapsed or refractory mantle cell lymphoma (MCL), a type of B cell lymphoma. This phase 3 study aims to understand how well these treatments work in patients who have already undergone previous therapies and have measurable disease. The study is sponsored by BeOne Medicines, previously known as BeiGene. Participants will receive either sonrotoclax plus zanubrutinib or zanubrutinib plus placebo, with all drugs administered orally. The treatments will be given in a double-blind, randomized manner across multiple centers. The study focuses on comparing the progression-free survival of participants over approximately 41 months, as assessed by an independent review committee. During the study, participants will be closely monitored for disease progression and safety outcomes. Assessments will include confirmation of diagnosis through tumor tissue analysis, evaluation of measurable disease lesions, and ongoing monitoring of organ function and performance status. The study duration and follow-up will allow researchers to assess long-term treatment effects and safety in the target adult population with relapsed or refractory MCL.

Researchers are assessing how well BGB-43395, a selective CDK4 inhibitor, works by itself or combined with fulvestrant, letrozole, or elacestrant in people with hormone receptor positive (HR+) and HER2-negative breast cancer, as well as other advanced solid tumors. This study is a Phase 1a/1b trial designed to find the best dosing of BGB-43395 and to evaluate its safety, tolerability, and early anti-tumor effects. Participants include those with metastatic or unresectable cancers that depend on CDK4, with specific groups defined for combinations with different drugs and prior treatment histories. The study involves giving BGB-43395 orally in planned doses, either alone or with standard doses of fulvestrant (by injection), letrozole (oral tablet), or elacestrant (oral tablet). Anti-diarrheal medication may also be given as needed. Different parts of the study focus on dose escalation to find the maximum tolerated dose and dose expansion to explore safety and effectiveness in defined patient groups. Participants may receive treatments for up to approximately 60 months, depending on the phase. Participants will be monitored for side effects, drug tolerance, and tumor response over the course of treatment. Researchers will collect data on adverse events, pharmacokinetics, and pharmacodynamics as well as objective tumor responses. Safety and effectiveness are tracked through regular visits involving clinical assessments, lab tests, and questionnaires. The total study duration for each participant can extend up to about five years, allowing for long-term monitoring of treatment effects and safety.